VPRIV(velaglucerase alfa for injection)
VPRIV Rx
Generic Name and Formulations:
Velaglucerase alfa 400 Units/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Company:
Shire US, Inc.
Select therapeutic use: Inborn errors of metabolism
Indications for VPRIV:
Long-term enzyme replacement therapy (ERT) in patients with Type 1 Gaucher disease.
Adults and Children:
<4yrs: not established. Give by IV infusion over 60 minutes. Individualize. ≥4yrs: 60 Units/kg every other week; adjust dose based on therapeutic goals. Begin treatment with Vpriv at the same dose when switching from imiglucerase.
Warnings/Precautions:
Monitor for hypersensitivity reactions; immediately discontinue and treat appropriately if occur. Temporarily discontinue and resume with increased infusion time, slowing infusion rate, or administer antihistamines, antipyretics, and/or corticosteroids if infusion-related reactions occur. Elderly. Pregnancy (Cat.B). Nursing mothers.
Pharmacological Class:
Lysosomal glucocerebroside-specific enzyme.
Adverse Reactions:
Infusion-related reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, upper respiratory tract infection, activated PTT prolonged, fatigue/asthenia, pyrexia.
Generic Availability:
NO
How Supplied:
Single-use vials—1 |
